NASDAQ:ALLOAllogene Therapeutics Stock Price, Forecast & News

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALLO stock has increased by 70.9% and is now trading at $42.82. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Allogene Therapeutics.

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Allogene Therapeutics.

Allogene Therapeutics Inc (NASDAQ:ALLO) released its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.58) EPS for the quarter, meeting analysts' consensus estimates of ($0.58). View Allogene Therapeutics' earnings history.

16 equities research analysts have issued 12-month price objectives for Allogene Therapeutics' stock. Their forecasts range from $27.00 to $70.00. On average, they expect Allogene Therapeutics' share price to reach $47.08 in the next year. This suggests a possible upside of 9.9% from the stock's current price. View analysts' price targets for Allogene Therapeutics.

News coverage about ALLO stock has trended neutral this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allogene Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Allogene Therapeutics.

Allogene Therapeutics saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 11,490,000 shares, a decline of 13.3% from the June 15th total of 13,250,000 shares. Based on an average daily volume of 1,210,000 shares, the short-interest ratio is currently 9.5 days. Currently, 20.2% of the shares of the company are sold short. View Allogene Therapeutics' Current Options Chain.

Some companies that are related to Allogene Therapeutics include NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), Neurocrine Biosciences (NBIX), argenx (ARGX), BIO-TECHNE (TECH), Qiagen (QGEN), Repligen (RGEN), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Novavax (NVAX), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA) and Iovance Biotherapeutics (IOVA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Teladoc Health (TDOC), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), bluebird bio (BLUE) and Sorrento Therapeutics (SRNE).

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALLO stock can currently be purchased for approximately $42.82.

Allogene Therapeutics has a market capitalization of $5.37 billion. The company earns $-184,590,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Allogene Therapeutics employs 122 workers across the globe.

The official website for Allogene Therapeutics is www.allogene.com.

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected]